Linear regression for systolic blood pressure, test for additive allele effects, subcohort without individuals on treatment for high blood pressure

Rank SNP name in MORGAM RS-code Chromosome Success Genotype N Mean coef (95% CI) nominal p-value tail-area FDR
1 2Q36_3_MG_433 rs2972147 2 98.5% C/C 747 83.549 -0.792
(-1.512, -0.072)		 0.03099 0.42438
C/T 861 84.067
T/T 249 85.092
2 MIA3_MG_430 rs17465637 1 99.3% A/A 134 82.530 -0.803
(-1.582, -0.024)		 0.04346 0.42438
A/C 683 83.839
C/C 1055 84.366
3 MTHFD1L_MG_423 rs12525353 6 99.4% A/A 2 87.000 -2.448
(-4.861, -0.035)		 0.04675 0.42438
A/C 72 81.403
C/C 1801 84.139
4 2Q36_3_MG_461 rs2943634 2 97.8% A/A 225 85.164 0.737
(0.002, 1.472)		 0.04932 0.42438
A/C 850 84.108
C/C 769 83.567
5 FMN2_MG_450 rs1456648 1 98.7% G/G 45 84.956 -0.961
(-1.924, 0.002)		 0.05052 0.42438
G/T 484 83.111
T/T 1332 84.299
6 10Q11_21_MG_439 rs501120 10 96.4% C/C 47 83.468 0.874
(-0.101, 1.849)		 0.07878 0.55147
C/T 445 85.256
T/T 1327 83.741
7 SEZ6L_MG_427 rs137209 22 99.6% A/A 185 83.022 -0.586
(-1.341, 0.168)		 0.12764 0.57306
A/G 865 83.769
G/G 828 84.521
8 SEZ6L_MG_457 rs6005016 22 98.9% A/A 4 86.000 1.145
(-0.692, 2.982)		 0.22194 0.57306
A/G 128 84.805
G/G 1734 83.977
9 5Q21_1_MG_455 rs383830 5 99.0% A/A 96 84.719 0.501
(-0.333, 1.335)		 0.23869 0.57306
A/T 599 84.453
T/T 1173 83.741
10 MIA3_MG_454 rs3008621 1 98.5% A/A 47 82.404 -0.581
(-1.557, 0.394)		 0.24276 0.57306
A/G 443 84.061
G/G 1368 84.097
11 10Q11_21_MG_443 rs687175 10 99.5% C/C 48 83.396 0.561
(-0.381, 1.503)		 0.24310 0.57306
C/T 507 84.811
T/T 1322 83.754
12 SEZ6L_MG_442 rs6005015 22 99.5% C/C 167 83.772 -0.447
(-1.210, 0.317)		 0.25143 0.57306
C/T 823 83.497
T/T 887 84.573
13 10Q11_21_MG_428 rs1746048 10 99.5% C/C 1324 83.748 -0.538
(-1.482, 0.407)		 0.26450 0.57306
C/T 505 84.850
T/T 47 83.085
14 5Q21_1_MG_436 rs449650 5 99.0% G/G 1173 83.761 -0.472
(-1.304, 0.360)		 0.26576 0.57306
G/T 597 84.430
T/T 97 84.742
15 SMAD3_MG_452 rs17228212 15 99.2% C/C 100 82.340 -0.469
(-1.303, 0.365)		 0.27063 0.57306
C/T 665 83.845
T/T 1105 84.286
16 10Q11_21_MG_440 rs559580 10 99.0% C/C 48 83.396 0.528
(-0.417, 1.472)		 0.27332 0.57306
C/T 501 84.796
T/T 1318 83.770
17 5Q21_1_MG_435 rs436495 5 98.8% A/A 109 84.872 0.448
(-0.367, 1.263)		 0.28095 0.57306
A/G 655 84.448
G/G 1099 83.771
18 9P21_3_MG_425 rs1333049 9 99.6% C/C 316 84.022 0.378
(-0.329, 1.085)		 0.29449 0.57306
C/G 915 84.255
G/G 647 83.706
19 10Q11_21_MG_429 rs1746049 10 99.5% C/C 1428 83.814 -0.552
(-1.586, 0.482)		 0.29543 0.57306
C/T 418 84.986
T/T 31 81.419
20 9P21_3_MG_420 rs10738610 9 99.1% A/A 628 83.745 -0.369
(-1.076, 0.338)		 0.30617 0.57306
A/C 915 84.257
C/C 326 84.015
21 10Q11_21_MG_456 rs513391 10 99.1% A/A 1316 83.780 -0.485
(-1.427, 0.456)		 0.31237 0.57306
A/C 504 84.754
C/C 49 83.082
22 10Q11_21_MG_458 rs622472 10 98.5% A/A 1303 83.782 -0.471
(-1.412, 0.469)		 0.32605 0.57306
A/C 504 84.778
C/C 50 83.040
23 SMAD3_MG_424 rs12913547 15 99.6% C/C 128 84.391 0.394
(-0.396, 1.185)		 0.32822 0.57306
C/T 740 84.486
T/T 1010 83.645
24 2Q36_3_MG_447 rs7597168 2 99.4% C/C 1047 83.915 -0.396
(-1.209, 0.416)		 0.33903 0.57306
C/T 720 83.949
T/T 107 85.570
25 5Q21_1_MG_441 rs565928 5 99.5% C/C 1175 83.782 -0.404
(-1.237, 0.428)		 0.34111 0.57306
C/T 606 84.403
T/T 96 84.583
26 12Q12_MG_448 rs7970834 12 99.5% G/G 581 83.824 0.211
(-0.498, 0.921)		 0.55912 0.90319
G/T 949 84.434
T/T 347 83.271
27 PSRC1_MG_460 rs599839 1 99.5% A/A 1080 84.022 0.179
(-0.620, 0.979)		 0.65998 0.97488
A/G 679 83.940
G/G 117 83.658
28 9P21_3_MG_421 rs10757283 9 99.4% C/C 548 84.152 0.142
(-0.565, 0.849)		 0.69336 0.97488
C/T 950 83.984
T/T 376 83.939
29 MTHFD1L_MG_445 rs6922269 6 99.3% A/A 99 83.162 -0.159
(-0.985, 0.666)		 0.70537 0.97488
A/G 665 83.910
G/G 1109 84.185
30 CELSR2_MG_438 rs4970834 1 99.4% C/C 1174 83.954 0.165
(-0.698, 1.028)		 0.70859 0.97488
C/T 626 84.232
T/T 75 83.240
31 SMAD3_MG_431 rs1866317 15 99.5% C/C 30 86.300 0.178
(-0.844, 1.200)		 0.73278 0.97488
C/G 453 84.007
G/G 1394 83.987
32 9P21_3_MG_437 rs496892 9 99.0% C/C 479 83.978 0.106
(-0.593, 0.805)		 0.76578 0.97488
C/T 951 84.339
T/T 437 83.572
33 19Q12_MG_446 rs7250581 19 97.9% A/A 46 85.804 0.146
(-0.835, 1.126)		 0.77125 0.97488
A/G 430 83.937
G/G 1371 84.051
34 19Q12_MG_422 rs11670734 19 99.5% C/C 142 84.106 0.102
(-0.678, 0.882)		 0.79776 0.97488
C/G 759 83.971
G/G 976 84.069
35 MTHFD1L_MG_449 rs12214306 6 99.2% C/C 0   0.209
(-2.092, 2.509)		 0.85901 0.97488
C/T 89 84.236
T/T 1782 84.008
36 SEZ6L_MG_426 rs137205 22 99.5% A/A 144 83.854 -0.071
(-0.850, 0.708)		 0.85904 0.97488
A/G 806 83.940
G/G 926 84.175
37 9P21_3_MG_459 rs7865618 9 98.8% A/A 613 84.192 0.063
(-0.632, 0.758)		 0.85982 0.97488
A/G 900 83.888
G/G 351 84.003
38 1Q31_2_MG_453 rs1936982 1 99.0% C/C 237 84.038 -0.054
(-0.772, 0.664)		 0.88261 0.97488
C/T 820 83.971
T/T 811 84.061
39 9P21_3_MG_451 rs1537378 9 98.1% A/A 282 84.078 -0.044
(-0.760, 0.673)		 0.90525 0.97488
A/G 892 83.893
G/G 676 84.163
40 CELSR2_MG_434 rs413380 1 99.5% C/C 1702 84.030 -0.044
(-1.596, 1.508)		 0.95591 0.98413
C/T 165 83.758
T/T 10 87.700
41 SEZ6L_MG_444 rs688034 22 99.5% C/C 976 84.165 -0.020
(-0.813, 0.773)		 0.96069 0.98413
C/T 769 83.889
T/T 131 83.824
42 10Q11_21_MG_432 rs2146807 10 99.3% C/C 14 84.071 0.002
(-1.219, 1.224)		 0.99682 0.99682
C/T 311 83.830
T/T 1547 84.075

adjusted for: cohort age1 sex

Updated on 2008-12-08